FibroGen, Inc. (FGEN)

NASDAQ: FGEN · IEX Real-Time Price · USD
24.39
+0.79 (3.35%)
At close: Feb 1, 2023, 4:00 PM
24.34
-0.05 (-0.21%)
Pre-market: Feb 2, 2023, 8:12 AM EST
3.35%
Market Cap 2.29B
Revenue (ttm) 122.91M
Net Income (ttm) -361.56M
Shares Out 93.96M
EPS (ttm) -3.89
PE Ratio n/a
Forward PE 61.35
Dividend n/a
Ex-Dividend Date n/a
Volume 1,114,533
Open 23.60
Previous Close 23.60
Day's Range 23.44 - 24.58
52-Week Range 7.81 - 24.58
Beta 0.72
Analysts Buy
Price Target 17.95 (-26.4%)
Earnings Date Feb 27, 2023

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human mon... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 14, 2014
Employees 566
Stock Exchange NASDAQ
Ticker Symbol FGEN
Full Company Profile

Financial Performance

In 2021, FibroGen's revenue was $235.31 million, an increase of 33.46% compared to the previous year's $176.32 million. Losses were -$290.02 million, 53.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for FGEN stock is "Buy." The 12-month stock price forecast is $17.95, which is a decrease of -26.40% from the latest price.

Price Target
$17.95
(-26.40% downside)
Analyst Consensus: Buy
Stock Forecasts

News

FibroGen to Present at SVB Securities Global Biopharma Conference

SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB Se...

2 hours ago - GlobeNewsWire

FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference

SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of Americ...

2 months ago - GlobeNewsWire

FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -18.07% and 53.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

FibroGen Reports Third Quarter 2022 Financial Results

SAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2022 and provided an update on the company's recent developments.

3 months ago - GlobeNewsWire

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management

SAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a royalty monetization financing with NovaQuest Capital Management (NovaQuest) that will result in procee...

3 months ago - GlobeNewsWire

FibroGen to Participate at Stifel 2022 Healthcare Conference

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 He...

3 months ago - GlobeNewsWire

Earnings Preview: FibroGen (FGEN) Q3 Earnings Expected to Decline

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

FibroGen to Report Third Quarter 2022 Financial Results

SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also c...

3 months ago - GlobeNewsWire

7 Unknown Biotech Stocks That Could Rocket in 2023

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

4 months ago - InvestorPlace

FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), provides an update to KSF's continued inves...

5 months ago - Business Wire

FibroGen (FGEN) Reports Q2 Loss, Misses Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 17.02% and 18.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

FibroGen Reports Second Quarter 2022 Financial Results

SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the company's recent developments.

6 months ago - GlobeNewsWire

FibroGen to Report Second Quarter 2022 Financial Results

SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also co...

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating FibroGen, Inc.

Wilmington, Delaware--(Newsfile Corp. - July 20, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of FibroGen, Inc. (NASDAQ: FGEN) on behalf of stockhol...

7 months ago - Newsfile Corp

FibroGen to Participate at William Blair Biotech Focus Conference 2022

SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William Blair ...

7 months ago - GlobeNewsWire

FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

- 73 Ambulatory DMD Patients Enrolled - - Topline Data Anticipated 2H:2023 -

8 months ago - GlobeNewsWire

FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigat...

8 months ago - Business Wire

FibroGen to Present at Jefferies Healthcare Conference

SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healt...

9 months ago - GlobeNewsWire

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 19.05% and 120.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

FibroGen Reports First Quarter 2022 Financial Results

SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2022 and provided an update on the company's recent developments.

9 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. is Investigating FibroGen, Inc.

Wilmington, Delaware--(Newsfile Corp. - May 5, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of FibroGen, Inc. (NASDAQ: FGEN) on behalf of stockholde...

9 months ago - Newsfile Corp

FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

FibroGen to Report First Quarter 2022 Financial Results

SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also condu...

10 months ago - GlobeNewsWire